155 related articles for article (PubMed ID: 9209903)
1. Prognostic markers in resectable non-small cell lung cancer.
Strauss GM
Hematol Oncol Clin North Am; 1997 Jun; 11(3):409-34. PubMed ID: 9209903
[TBL] [Abstract][Full Text] [Related]
2. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung.
Strauss GM; Kwiatkowski DJ; Harpole DH; Lynch TJ; Skarin AT; Sugarbaker DJ
J Clin Oncol; 1995 May; 13(5):1265-79. PubMed ID: 7738631
[TBL] [Abstract][Full Text] [Related]
3. Application of proteomics in non-small-cell lung cancer.
Cho WC
Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer.
Hung JJ; Yang MH; Hsu HS; Hsu WH; Liu JS; Wu KJ
Thorax; 2009 Dec; 64(12):1082-9. PubMed ID: 19778933
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of liver X receptor-alpha in resected stage II and III non-small-cell lung cancer.
Melloni G; Muriana P; Bandiera A; Fontana R; Maggioni D; Russo V; Doglioni C; Zannini P
Clin Respir J; 2018 Jan; 12(1):241-246. PubMed ID: 27401614
[TBL] [Abstract][Full Text] [Related]
6. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection.
Jiang W; Pang XG; Wang Q; Shen YX; Chen XK; Xi JJ
Clin Lung Cancer; 2012 Jul; 13(4):280-7. PubMed ID: 22178381
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Serum Tumor Markers in Patients With Stage III NSCLC Treated With Chemoradiotherapy.
Tokito T; Azuma K; Yamada K; Naito Y; Matsuo N; Ishii H; Natori H; Kinoshita T; Hoshino T
In Vivo; 2019; 33(3):889-895. PubMed ID: 31028213
[TBL] [Abstract][Full Text] [Related]
9. Molecular prognostic factors in resectable non-small cell lung cancer.
Vielh P; Spano JP; Grenier J; Le Chevalier T; Soria JC
Crit Rev Oncol Hematol; 2005 Mar; 53(3):193-7. PubMed ID: 15718145
[TBL] [Abstract][Full Text] [Related]
10. Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors.
Kang YK; Song YS; Cho S; Jheon S; Lee WW; Kim K; Kim SE
Lung Cancer; 2018 May; 119():1-6. PubMed ID: 29656743
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
12. Role of p53 and EGFR as prognostic biomarkers in stage I non-small cell lung cancer.
Donahue JM
J Surg Oncol; 2014 Aug; 110(2):97-8. PubMed ID: 24895315
[No Abstract] [Full Text] [Related]
13. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
[TBL] [Abstract][Full Text] [Related]
14. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].
Kayser G
Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246
[TBL] [Abstract][Full Text] [Related]
15. Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
Kim ES; Roy UB; Ersek JL; King J; Smith RA; Martin N; Martins R; Moore A; Silvestri GA; Jett J
J Thorac Oncol; 2019 Mar; 14(3):338-342. PubMed ID: 30709747
[No Abstract] [Full Text] [Related]
16. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.
Pelletier MP; Edwardes MD; Michel RP; Halwani F; Morin JE
Can J Surg; 2001 Jun; 44(3):180-8. PubMed ID: 11407827
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW
Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743
[TBL] [Abstract][Full Text] [Related]
18. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.
D'Amico TA; Massey M; Herndon JE; Moore MB; Harpole DH
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):736-43. PubMed ID: 10096969
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
